Join our experts on October 2, 2019 at the Current Uses & Future Applications in Nanomedicine Event to learn about our new exciting technology.
Hear presentations from Dr. Jiang Zhu, Dr. John Lewis, Dr. Andy Geall and Dr. Euan Ramsay; their presentation summaries can be found below.
More information to follow.
RSVP for the event here
- Suicide gene therapy of solid tumors using Fusogenix LNP
Summary: While targeted therapies and precision medicines have become key treatments for solid tumors, these approaches are rarely curative as patients will eventually become resistant. To address this, we developed an effective gene therapy approach that specifically exploits their unique transcriptional activation state. I will detail our development of a Fusogenix lipid nanoparticle formulation to deliver a p53-driven inducible suicide gene to solid tumors.
Dr. Geall - Non-viral Delivery of Self-amplifying mRNA Vaccines
Summary: mRNA vaccines are being developed as a platform technology with potential to be used for a broad range of targets. Self-amplifying mRNA vaccines represent some of the most potent examples of this new platform technology. Their synthetic production methods, combined with the modern tools of bioinformatics and synthetic biology, enable these vaccines to be produced rapidly from an electronic gene sequence.
Non-viral delivery of these novel mRNA vaccines means that issues of anti-vector immunity are avoided and potent immune responses are elicited at low doses of the nucleic acid. Preclinical proof of concept has so far been achieved for influenza, RSV, rabies, CMV, and HIV. Like other types of nucleic acid vaccines, these vaccines have the potential to draw on the positive attributes of live-attenuated vaccines while obviating many potential safety limitations. Hence, this approach could enable the concept of vaccines on demand as a rapid response to a real threat rather that the deployment of strategic stockpiles based on epidemiological predictions of a possible threat.
Dr. Ramsay -
Presentation on the requirements that led to the development of NxGen and demonstrate its utility in the formulation of liposomes, PLGA nanoparticles and lipid nanoparticles for the delivery of a range of nucleic acids (such as mRNA, siRNA and pDNA).
He will show how these particles compare favorably (size, poly and EE) to those produced on a staggered herringbone mixer and how these formulations can be scaled using the NxGen mixer on the NanoAssemblr® platform.
Dr. Zhu - Presentation topic and summary coming soon